An Interview with Nicola Ferro: Discovering The iDPP@CLEF Challenge 2022
BRAINTEASER is excited to take part in the iDPP@CLEF Challenge 2022 happening on 5-8 September, We recently spoke about the event with organiser and full-time computer science professor Nicola Ferro at the University of Padua, Italy. Continue...
BRAINTEASER presents its first open evaluation challenge at ECIR
ECIR is the premier European conference on Information Retrieval and Information Access (CORE Rank A). ECIR teams up with CLEF in order to strengthen the European research community and organizes a session dedicated to presenting the ongoing labs...
iDPP@CLEF 2022: Intelligent Disease Progression Prediction at CLEF
Amyotrophic Lateral Sclerosis (ALS) is a chronic disease, characterized by progressive or alternate impairment of neurological functions (motor, sensory, visual, cognitive). Patients have to manage alternated periods in hospital with care at home,...
BRAINTEASER Focus Groups: suitable exploitation routes co-design first online workshop
The first out of four BRAINTEASER Focus Groups dedicated to the project’s results exploitation and sustainability, was held on February 1st 2022. These exploitation Focus Groups aim to broaden the project’s vision on users and market needs,...
The importance of patient stratification methods based on AI for disease onset and progression prediction
The inherent complexity of degenerative neurological diseases, such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), and the particular requirement for unravelling new biomarkers warrant a novel approach that integrates...
Updates on the project’s liaison with relevant initiatives and projects
As part of its dissemination core set of activities, BRAINTEASER reached out to other EU funded Horizon2020 projects with similar objectives and common challenges with the aim to identify potential areas of collaboration. A first meeting took place...
Suitable exploitation routes co-design: BRAINTEASER approach to results’ sustainability and commercialisation strategy
One of the main objectives of the BRAINTEASER project is to exploit its results with the ultimate aim of improving care and quality of life of ALS and MS patients. To accompany the BRAINTEASER Consortium towards the most suitable results’...
BRAINTEASER is building up its community of practice
The BRAINTEASER community of practice will focus on the clinical use of Artificial Intelligence and digital tools to manage ALS and MS disease. It will be an innovation community to create new breakthrough ideas, approaches, and knowledge. The...
Special Session on “Artificial intelligence and statistical methods for neurodegenerative diseases” at the CIBB 2021
On November 16th, the 17th Conference on Computational Intelligence Methods for Bioinformatics and Biostatistics (CIBB 2021) hosted the Special Session “Artificial Intelligence and Statistical Methods for Neurodegenerative Diseases”. The special...
BRAINTEASER Open Evaluation Challenges launch
The Intelligent Disease Progression Prediction (iDPP) challenge aims at designing and developing an evaluation infrastructure for AI algorithms able to: ● better describe disease mechanisms; ● ...
BRAINTEASER at the DHS Summit – Panel discussion “Cultural and regional aspects influencing digital health adoption and upscale”
On the 24th of November 2021, The Digital Health Society (DHS) and the ECHAlliance hosted a panel session within the Digital Health Society Summit 2021, on “Cultural and regional aspects influencing digital health adoption and upscale”, involving...
BRAINTEASER: Interview with Pieter van Galen Patient advocate, European Multiple Sclerosis Platform (EMSP)
The use of technologies in the treatment and management of multiple sclerosis: the experience of Pieter van Galen, Patient advocate, European Multiple Sclerosis Platform (EMSP) Pieter van Galen is from the Netherlands and studied Business &...
Get to Know more about Amyotrophic Lateral Sclerosis – Can ecological factors affect ALS disease phenotype and progression?
BRAINTEASER project aims to understand if different ecological factors can affect disease phenotype and progression of patients with amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). Few studies investigated the spatial distribution...
Get to Know more about Amyotrophic Lateral Sclerosis – Hypothesis Amyotrophic lateral sclerosis and environmental pollutants
BRAINTEASER project aims to understand if different ecological factors can affect disease phenotype and progression of patients with amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). The “Amyotrophic Lateral Sclerosis” campaign wants...
Register for the CIBB 2021 Special Session: Artificial intelligence and statistical methods for neurodegenerative diseases
The 17th Computational Intelligence Methods for Bioinformatics and Biostatistics conference (CIBB 2021) will happen online on 15 - 17 November, 2021. The full agenda is now available. The session will dig into how big data in healthcare and...
![[Get to Know more about Amyotrophic Lateral Sclerosis] The use of biotelemetry to explore disease](https://brainteaser.health/wp-content/uploads/2021/10/Brainteaser-GIFs-NewsletterWebpage-1080x675.png)
[Get to Know more about Amyotrophic Lateral Sclerosis] The use of biotelemetry to explore disease
BRAINTEASER project aims to support patients with amyotrophic lateral sclerosis and multiple sclerosis and their clinicians. “Amyotrophic Lateral Sclerosis” campaign wants to bring attention to this condition and analyse the variables that might...
![[Get to Know more about Multiple Sclerosis] Air pollution and multiple sclerosis risk](https://brainteaser.health/wp-content/uploads/2021/09/Brainteaser-GIFs-NewsletterWebpage-2-1080x675.jpg)
[Get to Know more about Multiple Sclerosis] Air pollution and multiple sclerosis risk
BRAINTEASER project aims to support patients with amyotrophic lateral sclerosis and multiple sclerosis and their clinicians. "Get to Know more about Multiple Sclerosis" campaign wants to bring attention to this condition and on the variables that...
BRAINTEASER: Special Session on “Artificial intelligence and statistical methods for neurodegenerative diseases” at the 17th Conference on Computational Intelligence Methods for Bioinformatics and Biostatistics (CIBB 2021)
On 15-17 November 2021, the 17th Conference on Computational Intelligence Methods for Bioinformatics and Biostatistics (CIBB 2021) will take place online. In this context, the University of Padova (Padova, Italy), member of the BRAINTEASER...
BRAINTEASER: Open co-design workshop on next generation tools to manage ALS and MS
On June 3rd took place the first open Co-design workshop of BRAINTEASER to present and discuss the digital tools that the consortium is in process of design and development. The workshop was conducted by Manuel Ottaviano (Universidad Politécnica of...
The European Brain Council launches “RETHINKING MS in times of COVID-19″ on the occasion of World Multiple Sclerosis Day
On the occasion of the World Multiple Sclerosis Day (30 May 2021), the European Brain Council (EBC), member of the BRAINTEASER Consortium, announced the release of its new policy paper, “RETHINKING MS in times of COVID-19”. This new paper is part...